<span item_type="fundamental" item_id="beaf935b16eafbe1ad0b18789198db30" counter_id="ST/US/EDSA" env="prod"></span><span item_type="announcement" item_id="592948611826782593" env="prod"></span><p>Revenue: As of FY2025, the actual value is USD 0.</p><p>EPS: As of FY2025, the actual value is USD -1.27, missing the estimate of USD -1.17.</p><p></p><h3>Operating Expenses</h3><ul><li>Total operating expenses increased by $0.9 million to $7.9 million compared to $7.0 million for the prior year.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1540159/000117184325007913/exh_991.htm"></span></li><li>Research and development expenses rose by $0.8 million to $3.7 million, primarily due to increased manufacturing-related activities and preparations for a Phase 2 clinical study of EB06 in vitiligo patients, as well as costs related to the completion of a Phase 3 study of paridiprubart (EB05) and drug supply costs for an ongoing U.S. government study of paridiprubart.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1540159/000117184325007913/exh_991.htm"></span></li><li>General and administrative expenses increased by $0.1 million to $4.2 million, mainly due to an increase in noncash share-based compensation, partially offset by a decrease in professional fees.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1540159/000117184325007913/exh_991.htm"></span></li></ul><h3>Other Income</h3><ul><li>Total other income decreased by $0.1 million to $0.7 million, primarily due to a decrease in interest income, partially offset by an increase in reimbursement funding from the Canadian government’s Strategic Innovation Fund.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1540159/000117184325007913/exh_991.htm"></span></li></ul><h3>Net Loss</h3><ul><li>Edesa reported a net loss of $7.2 million, or $1.27 per common share, compared to a net loss of $6.2 million, or $1.93 per common share, for the previous year.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1540159/000117184325007913/exh_991.htm"></span></li></ul><h3>Cash Flow</h3><ul><li>Net cash used in operating activities was - $7.3 million, compared to - $4.9 million in the prior year.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1540159/000117184325007913/exh_991.htm"></span></li><li>Net cash provided by financing activities was $17.0 million, compared to $0.6 million in the prior year.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1540159/000117184325007913/exh_991.htm"></span></li><li>Cash and cash equivalents at the end of the period were $10.8 million, up from $1.0 million at the beginning of the period.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1540159/000117184325007913/exh_991.htm"></span></li></ul><h3>Outlook / Guidance</h3><ul><li>Edesa anticipates initiating patient recruitment for a Phase 2 vitiligo study by midyear 2026, subject to manufacturing and regulatory approvals. The company is also pursuing development and commercialization partnerships for paridiprubart and exploring expedited regulatory pathways. Strategic initiatives include securing non-dilutive funding and collaborative arrangements to advance their programs.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1540159/000117184325007913/exh_991.htm"></span></li></ul>

Edesa Biotech | 8-K: FY2025 Revenue: USD 0